Acral Melanoma, Melanoma of Skin, Stage II Melanoma
Conditions
Keywords
Melanoma of skin, Acral melanoma, Stage II melanoma, Toripalimab, Recombinant human endostatin (Endostar), Perioperative immunotherapy, PD-1 inhibitor, Anti-angiogenic therapy, Phase II study
Brief summary
This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer: 1. Does this combination improve the 2-year recurrence-free survival (2y-RFS) compared to historical data? 2. Is the treatment safe and tolerable for patients? Participants will: 1. Receive 2 cycles of toripalimab before surgery (neoadjuvant therapy). 2. Undergo surgical removal of the tumor. 3. Post surgery, receive toripalimab every 2 weeks + Endostar (72-hour continuous infusion every 4 weeks) for up to 6 cycles (Endostar) or 11 cycles (toripalimab). 4. Be monitored for tumor recurrence, side effects, and survival for up to 2 years after treatment. This is a single-arm, multicenter study involving 58 patients across several hospitals in China. Results will help determine if this combination could become a new standard adjuvant therapy for stage II melanoma.
Interventions
DRUGToripalimab combined with Endostar
1. Neoadjuvant Phase: 2 doses of toripalimab (240 mg IV, Q2W) before surgery. 2. Surgery: Tumor resection within 2 weeks after the last neoadjuvant dose. 3. Adjuvant Phase: 1) Toripalimab: 240 mg IV every 2 weeks (up to 11 cycles); 2) Endostar: 210 mg (72-hour continuous IV infusion) every 4 weeks (up to 6 cycles).
Sponsors
Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai 411 hospital
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years, regardless of gender; 2. ECOG performance status: 0-1; 3. Patients with histologically or cytologically confirmed cutaneous or acral malignant melanoma, excluding mucosal and uveal melanoma; 4. Patients with BRAF, CKIT, and NRAS gene test results; 5. Treatment-naïve patients who have not received prior anti-tumor therapy; 6. Clinical stage II (AJCC 8th edition, 2017); 7. Laboratory tests must meet the following criteria: 1. Hematology: Hemoglobin (Hb) ≥90 g/L (no transfusion within 14 days); absolute neutrophil count (ANC) ≥1.5×10\^9/L; platelet count (PLT) ≥100×10\^9/L; 2. Biochemistry: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN; serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance \>50 μmol/L; 3. Coagulation: Activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN; 4. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%; 8. Female patients must agree to use contraception (e.g., intrauterine device \[IUD\], oral contraceptives, or condoms) during the study and for 6 months after study completion. A negative serum or urine pregnancy test within 7 days before enrollment is required, and patients must be non-lactating. Male patients must agree to use contraception during the study and for 6 months after study completion; 9. Patients must voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
Exclusion criteria
1. History of allergic reactions to biological products; 2. Patients with prior or concurrent malignancies within 5 years (except cured basal cell carcinoma of skin or carcinoma in situ of cervix); 3. Any active autoimmune disease or history of autoimmune disorders (including but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma requiring bronchodilators for medical intervention). Exceptions include: vitiligo, psoriasis, alopecia not requiring systemic therapy, well-controlled type I diabetes, or hypothyroidism with normal thyroid function on replacement therapy; 4. Requirement for immunosuppressive therapy using systemic or absorbable topical corticosteroids (equivalent to prednisone \>10mg/day) within 2 weeks prior to first dose; 5. Any history or evidence of bleeding diathesis regardless of severity; grade ≥3 bleeding events per CTCAE v5.0 within 4 weeks prior to first dose; or presence of unhealed wounds, fractures, active gastrointestinal ulcers, ulcerative colitis, tumors with active bleeding, or other conditions deemed by investigators to potentially cause gastrointestinal hemorrhage or perforation; 6. Patients with severe and/or uncontrolled comorbidities including: 1. Poorly controlled hypertension (SBP ≥150 mmHg or DBP ≥90 mmHg); 2. Unstable angina, myocardial infarction, ≥grade 2 congestive heart failure, or arrhythmias requiring treatment (including QTc ≥480ms) within 6 months prior to first dose; 3. Active or uncontrolled severe infections (≥grade 2 per CTCAE); 4. Clinically significant liver disease including viral hepatitis (active HBV infection with HBV DNA \>1×10³ copies/mL or \>500 IU/mL; HCV infection with HCV RNA \>1×10³ copies/mL or \>100 IU/mL), decompensated liver disease, or chronic hepatitis requiring antiviral therapy; 5. HIV-positive status; 6. Poorly controlled diabetes (fasting glucose ≥grade 2 per CTCAE); 7. Urinalysis showing proteinuria ≥++ with 24-hour urinary protein \>1.0 g; 7. Administration of live vaccines within 4 weeks prior to treatment or anticipated need during study; 8. Other conditions deemed by investigators to potentially lead to premature study termination, including: severe comorbidities (including psychiatric disorders) requiring concomitant therapy, significant laboratory abnormalities, or social/family factors that may compromise patient safety or data/sample collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year recurrence-free survival rate (2-year RFS rate) | From enrollment to the end of the 2nd year of follow-up |
Secondary
| Measure | Time frame |
|---|---|
| 1-year distant metastasis-free survival rate (1-year DMFS rate) | From enrollment to the end of the 1st year |
| Overall survival (OS) | Through study completion, an average of 3 years |
| 1-year recurrence-free survival rate (1-year RFS rate) | From enrollment to the end of the 1st year |
| 2-year distant metastasis-free survival rate (2-year DMFS rate) | From enrollment to the end of the 2nd year |
Countries
China
Contacts
Primary ContactChunmeng Wang, Dr.
Outcome results
None listed